Torrent is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $10.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Torrent's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Aug 2024 | $7.7B |
| Otezla | Amgen | Generic | 2028 | Settled in 2021, terms confidential | $2.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Torrent's share of it.